Altered gp130 signalling ameliorates experimental colitis via myeloid cell-specific STAT3 activation and myeloid-derived suppressor cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Däbritz, Jan ^a,b   Judd, Louise M ^a,b   Chalinor, Heather V ^a   Menheniott, Trevelyan R ^a,b   Giraud, Andrew S ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 130; IL6ST PROTEIN, MOUSE; LIPOPOLYSACCHARIDE; STAT3 PROTEIN; STAT3 PROTEIN, MOUSE;

ANIMAL; COLITIS; COLON; COMPARATIVE STUDY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; PERITONEUM MACROPHAGE; SPLEEN;

ANIMALS; COLITIS; COLON; CYTOKINE RECEPTOR GP130; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; SPLEEN; STAT3 TRANSCRIPTION FACTOR;

EID: 84957581230     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20584     Document Type: Article

References (50)

1. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 22, 238-244 (2010).
2. Greten, T. F., Manns, M. P., Korangy, F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 11, 802-807 (2011).
3. Ribechini, E., Greifenberg, V., Sandwick, S., Lutz, M. B. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol. 199, 273-281 (2010).
4. Gabrilovich, D. I., Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9, 162-174 (2009).
5. Manjili, M. H., Wang, X. Y., Abrams, S. Evolution of Our Understanding of Myeloid Regulatory Cells: From MDSCs to Mregs. Front Immunol. 5, 303 (2014).
6. Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12, 253-268 (2012).
7. Haile, L. A., Greten, T. F., Korangy, F. Immune suppression: the hallmark of myeloid derived suppressor cells. Immunol Invest. 41, 581-594 (2012).
8. Condamine, T., Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19-25 (2011).
9. Trikha, P., Carson, W. E. 3rd. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta. 1846, 55-65 (2014).
10. Ostrand-Rosenberg, S., Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 182, 4499-4506 (2009).
11. Ostanin, D. V., Bhattacharya, D. Myeloid-derived suppressor cells in the inflammatory bowel diseases. Inflamm Bowel Dis. 19, 2468-2477 (2013).
12. Geremia, A., Biancheri, P., Allan, P., Corazza, G. R., Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev. 13, 3-10 (2014).
13. Haile, L. A. et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology. 135, 871-881, 881 e871-875 (2008).
14. Guan, Q. et al. The role and potential therapeutic application of myeloid-derived suppressor cells in TNBS-induced colitis. J Leukoc Biol. 94, 803-811 (2013).
15. Zhang, J. et al. Protein tyrosine phosphatase 1B deficiency ameliorates murine experimental colitis via the expansion of myeloidderived suppressor cells. PLoS One. 8, e70828 (2013).
16. Zhang, R. et al. Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin Exp Immunol. 164, 417-427 (2011).
17. Su, H., Cong, X., Liu, Y. L. Transplantation of granulocytic myeloid-derived suppressor cells (G-MDSCs) could reduce colitis in experimental murine models. J Dig Dis. 14, 251-258 (2013).
18. Dabritz, J. Granulocyte macrophage colony-stimulating factor and the intestinal innate immune cell homeostasis in Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 306, G455-465 (2014).
19. Silver, J. S., Hunter, C. A. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol. 88, 1145-1156 (2010).
20. Jarnicki, A., Putoczki, T., Ernst, M. Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div. 5, 14 (2010).
21. Reindl, W., Weiss, S., Lehr, H. A., Forster, I. Essential crosstalk between myeloid and lymphoid cells for development of chronic colitis in myeloid-specific signal transducer and activator of transcription 3-deficient mice. Immunology. 120, 19-27 (2007).
22. Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 10, 39-49 (1999).
23. Tebbutt, N. C. et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med. 8, 1089-1097 (2002).
24. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitisassociated tumorigenesis. Cancer Cell. 15, 91-102 (2009).
25. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15, 103-113 (2009).
26. Olszak, T. et al. Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature. 509, 497-502 (2014).
27. Alex, P. et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 15, 341-352 (2009).
28. Beck, P. L. et al. Inducible nitric oxide synthase from bone marrow-derived cells plays a critical role in regulating colonic inflammation. Gastroenterology. 132, 1778-1790 (2007).
29. Ito, R. et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 146, 330-338 (2006).
30. Azuma, Y. T. et al. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 16, 1017-1028 (2010).
31. Grobeta, P., Doser, K., Falk, W., Obermeier, F., Hofmann, C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis. 18, 1900-1909 (2012).
32. Duan, L. et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+ ) regulatory T-cell responses in mice. Mol Med. 18, 753-761 (2012).
33. Sattler, S. et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J Autoimmun. 50, 107-122 (2014).
34. Bronte, V., Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 5, 641-654 (2005).
35. Krieglstein, C. F. et al. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J Exp Med. 194, 1207-1218 (2001).
36. Gobert, A. P. et al. Protective role of arginase in a mouse model of colitis. J Immunol. 173, 2109-2117 (2004).
37. Weisser, S. B. et al. Arginase activity in alternatively activated macrophages protects PI3Kp110delta deficient mice from dextran sodium sulfate-induced intestinal inflammation. Eur J Immunol (2014).
38. Zhang, R. et al. Up-regulation of Gr1+ CD11b+ population in spleen of dextran sulfate sodium administered mice works to repair colitis. Inflamm Allergy Drug Targets. 10, 39-46 (2011).
39. Oh, S. Y., Cho, K. A., Kang, J. L., Kim, K. H., Woo, S. Y. Comparison of experimental mouse models of inflammatory bowel disease. Int J Mol Med. 33, 333-340 (2014).
40. Sander, L. E. et al. Gp130 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation. J Immunol. 181, 3586-3594 (2008).
41. Singh, U. P. et al. Role of resveratrol-induced CD11b(+) Gr-1(+) myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3(+ ) T cells and amelioration of chronic colitis in IL-10(?/? ) mice. Brain Behav Immun. 26, 72-82 (2012).
42. Hokari, R. et al. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic Biol Med. 31, 153-163 (2001).
43. Canto, E. et al. Interleukin-19 impairment in active Crohn's disease patients. PLoS One. 9, e93910 (2014).
44. Yamamoto-Furusho, J. K. et al. Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. Hum Immunol. 72, 1029-1032 (2011).
45. Azuma, Y. T. et al. Interleukin-19 is a negative regulator of innate immunity and critical for colonic protection. J Pharmacol Sci. 115, 105-111 (2011).
46. Seidelin, J. B., Rogler, G., Nielsen, O. H. A role for interleukin-33 in T(H)2-polarized intestinal inflammation? Mucosal Immunol. 4, 496-502 (2011).
47. Elson, C. O., Sartor, R. B., Tennyson, G. S., Riddell, R. H. Experimental models of inflammatory bowel disease. Gastroenterology. 109, 1344-1367 (1995).
48. Leal, M. C., Dabritz, J. Immunoregulatory Role of Myeloid-derived Cells in Inflammatory Bowel Disease. Inflamm Bowel Dis. 21, 2936-2947 (2015).
49. Peterson, A. J. et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology. 139, 2005-2017 (2010).
50. Schneider, C. A., Rasband, W. S., Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9, 671-675 (2012).